lupkynis
otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - imunosupresoare - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).
lupkynis 7,9 mg
millmount healthcare limited - irlanda - voclosporinum - caps. moi - 7,9mg - imunosupresoare inhibitori de calcineurina
paxlovid
pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.
ciclosporina sandoz 10 mg
novartis pharma gmbh - germania - ciclosporinum - caps. moi - 10mg - imunosupresoare inhibitori de calcineurina
ciclosporina sandoz 25 mg
novartis pharma gmbh - germania - ciclosporinum - caps. moi - 25mg - imunosupresoare inhibitori de calcineurina
ciclosporina sandoz 50 mg
novartis pharma gmbh - germania - ciclosporinum - caps. moi - 50mg - imunosupresoare inhibitori de calcineurina
ciclosporina sandoz 100 mg
novartis pharma gmbh - germania - ciclosporinum - caps. moi - 100mg - imunosupresoare inhibitori de calcineurina
sandimmun neoral 100 mg capsule moi
novartis pharma ag - cyclosporinum - capsule moi - 100 mg
sandimmun neoral 25 mg capsule moi
novartis pharma ag - cyclosporinum - capsule moi - 25 mg
sandimmun neoral 50 mg capsule moi
novartis pharma ag - cyclosporinum - capsule moi - 50 mg